CHRONIC LYMPHOCYTIC LEUKEMIA

This early-stage study tested a new drug called odronextamab (REGN1979) in 200 people with B-cell blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia that had stopped responding to prior treatments. The goal was to check the drug's safety and find the right d…

This study tested the safety of an experimental drug called cirmtuzumab in 3 people with chronic lymphocytic leukemia (CLL) who had already received the drug before. Cirmtuzumab is a lab-made antibody that attaches to a protein called ROR1 found on CLL cells, aiming to block thei…

This study tested a combination of drugs (ofatumumab, methylprednisolone, and lenalidomide) in 45 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal was to see if the treatment could make all signs of cancer disappear or shrink significantl…

This study looked at whether giving the drug ibrutinib early to people with chronic lymphocytic leukemia (CLL) who have high-risk features but no symptoms is better than waiting until symptoms develop. It involved 23 participants and measured how many achieved complete or partial…

This study tested a combination of two drugs, idelalisib and ofatumumab, in 27 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had not received prior treatment. The goal was to see how well the drugs worked together to shrink or control the …

This early-phase study tested a combination of two drugs, acalabrutinib and obinutuzumab, in 69 people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal was to see if the combination was safe and could shrink or control the cancer. Participants included t…

This study tested a drug called acalabrutinib in 48 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had a high-risk genetic change (deletion 17p). The goal was to see how well the drug shrank tumors. Results showed that many patients had a p…

This early-phase trial tested a new drug called BR101801 in 26 adults with advanced blood cancers like lymphoma and leukemia that had not responded to other treatments. The main goals were to find a safe dose and check for side effects. The study had two parts: one to determine t…

This study tested a drug called acalabrutinib in 552 adults with chronic lymphocytic leukemia (CLL), a type of blood cancer. Participants took the drug twice daily for up to 48 cycles (about 4 years). The main goal was to check safety and side effects, and researchers also looked…

This study tested an experimental pill called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other B-cell non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was…

This study tested whether Panzyga, an antibody treatment, can prevent serious infections in people with chronic lymphocytic leukemia (CLL) who also have low antibody levels. About 247 adults with CLL received either Panzyga or a placebo. The goal was to see if Panzyga reduces maj…

This study tested whether the drug ibrutinib, given with vaccines, can help people with early-stage but high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) live longer without their cancer getting worse. The trial included 42 participants who had not …

This study tested a two-step treatment for people with chronic lymphocytic leukemia (CLL) who had not received prior therapy. First, participants received a standard chemotherapy combination (bendamustine and rituximab), followed by a year of the oral drug venetoclax. The goal wa…

This study tested a combination of three drugs—ibrutinib, fludarabine, and pembrolizumab—in 15 people with high-risk or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see if the combination could produce a complete resp…

This study tested a combination of two drugs, ibrutinib and obinutuzumab, in people aged 65 and older with untreated chronic lymphocytic leukemia (CLL) who cannot have chemotherapy. The goal was to see if the combo safely reduces the amount of cancer cells in the body. The trial …

This study tested a new drug (BGB-10188) alone or with other drugs in 97 people with certain blood cancers or advanced solid tumors. The goal was to find the safest and most effective dose. However, the best dose could not be determined for all groups because not enough data was …

This study tested a two-step stem cell transplant for 62 people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor immune cells followed by a stem cell transplant. The goa…

This early-phase study tested a new approach for people with advanced B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL) that had returned or not responded to standard treatments. Researchers took patients' own immune cells (T cells) and added a special receptor (a…

This study tested different combinations of immune-suppressing drugs to prevent graft-versus-host disease (GVHD) in 174 patients with blood cancers who received a stem cell transplant from an unrelated donor. The goal was to find the most effective approach to reduce severe GVHD,…

This early-phase study tested adding the cholesterol-lowering drug pitavastatin to the standard targeted therapy venetoclax for people with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML). The main goal was to find a safe dose and check for side effects. Only 6…

This study tested whether regular phone calls from a nurse could help people with chronic lymphocytic leukemia (CLL) stick to their chemotherapy plan (FCR) and have fewer side effects. Sixty patients took part. The goal was to see if the calls improved how much of the planned che…

This study looked at whether a stem cell transplant using a patient's own cells can help control chronic lymphocytic leukemia (CLL) in people under 65 who had not yet been treated. The main goal was to see how long the disease stayed under control. The study found that the transp…

This study looked at whether giving vitamin D supplements to people with newly diagnosed non-Hodgkin lymphoma or chronic lymphocytic leukemia who have low vitamin D levels could improve their outcomes. About 197 participants received either a low or high dose of vitamin D alongsi…

This early-phase study tested a new cell therapy called IOV-2001 in 7 patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that had stopped responding to standard treatments. The therapy uses a patient's own immune cells to fight the cancer. The main goals wer…

This early-stage study tested the safety and highest tolerable dose of a new, genetically modified immune cell therapy called PRGN-3007 UltraCAR-T in adults with advanced blood cancers and triple-negative breast cancer. The main goal was to see how much of the treatment patients …

This study aimed to find biological markers that could predict early on whether the drug ibrutinib would work in people with a high-risk form of chronic lymphocytic leukemia (CLL) that has a TP53 mutation. Researchers followed 56 patients who were already planning to take ibrutin…

This study tested a personalized geriatric optimization plan (GO!) in 30 patients aged 60 and older who were getting a stem cell transplant for blood cancers or bone marrow failure. The plan included tailored changes to diet, sleep, activity, and medications. The goal was to see …

This study surveyed 218 adults with chronic lymphocytic leukemia or multiple myeloma to learn about the financial difficulties they face from cancer treatment. Researchers asked patients about money problems over the past year and also surveyed doctors and clinics. The goal is to…

This study tracked 89 Japanese adults with chronic lymphocytic leukemia (CLL) who had already received 24 months of treatment with Venetoclax, with or without Rituximab. The goal was to see how many had undetectable minimal residual disease (uMRD), a sign of deep remission. Resea…